


SinaDoxosome



Metastatic ovarian cancer

Pegylated liposomal doxorubicin (PLD) is indicated for:

- 1 Patients with platinum-sensitive ovarian cancer
- 2 Patients with platinum-resistant or platinum refractory ovarian cancer
- 3 Patients who are allergic to Platinum-based compound

Primary systemic therapy

Carboplatin AUC 5 IV + PEGylated liposomal doxorubicin 30 mg/m² IV, repeat every 28 days.



For high-grade serous stage I and stage II-IV



For all other stage I ovarian cancers

PLD 50 mg/m²



Versus

Topotecan 1.5 mg/m²



Results:



- Similar overall response rate (ORR, 20% versus 17%)
- Similar time to progression (TTP, 22 versus 20 weeks)
- Similar median overall survival (OS, 66 versus 56 weeks)
- Less serious (grade 3/4) myelotoxicity, including neutropenia (12% versus 71%) and thrombocytopenia (1% versus 35%)